Status and phase
Conditions
Treatments
About
The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS
Full description
This first-in-human, Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics (PK) of QRL-201 administered intrathecal (IT) to participants with Amyotrophic Lateral Sclerosis. Two dose escalation cohorts of 8 participants each, followed by an additional 48 participants, receiving the study drug in a 6:2 ratio of QRL-201 to placebo.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
64 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
QurAlis Corporation
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal